CSPC PHARMA (01093.HK): Innovative Chemical Drug SYH2083 Eye Drops Obtains Clinical Trial Approval in China for Dry Eye Disease

NewTimeSpace News: On 8 September 2026, CSPC Pharmaceutical Group Limited (stock code: 01093) issued a voluntary announcement stating that SYH2083 Eye Drops, a Category 1 innovative chemical drug developed by the group, had been approved by the National Medical Products Administration for clinical trials in China.

According to the announcement, the product is a small-molecule ophthalmic formulation with a novel mechanism of action, which treats ocular surface inflammatory diseases by reducing the adhesion and activation of T lymphocytes and lowering pro-inflammatory signalling. Preclinical studies demonstrated significant pharmacological activity in a mouse dry eye model, with a clear mechanism of action and promising clinical development potential.

The indication approved for this clinical trial is dry eye disease, and the product also has potential to be extended to other inflammatory ocular surface diseases such as allergic conjunctivitis in the future. The company said the approval further enriches the group's innovative drug pipeline in the ophthalmology field.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.